当前位置： SCI文献检索 > AUTOIMMUNITY REVIEWS期刊下所有文献 > Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature.

Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature.

Abstract：

OBJECTIVES:To assess the efficacy and safety of Rituximab (RTX) in adult primary central nervous system vasculitis (PCNSV). METHODS:We retrospectively assessed the effect of RTX in 6 patients with PCNSV. Five of the 6 were refractory to high dose glucocorticoids (GCs) and/or conventional immunosuppressants (IS). The sixth was newly diagnosed and received RTX in combination with GCs. Clinical evaluation, laboratory tests, and imaging modalities were performed at initial RTX administration and during the follow-up. Treatment response was assessed using the treating physician's global opinion regarding response and the degree of disability using the modified Rankin scale (mRS). We also performed a literature review for previous use of RTX in PCNSV using PubMed, Ovid Medline, and the Cochrane library. RESULTS:The six patients (3 females) had a median age at diagnosis of 50.5 years (range 17-68 years). All had active disease when RTX was started. In 4 patients, RTX administration was associated with a marked reduction in the number of flares (from 18 before starting RTX to 3 after). One patient, after an initial improvement, had 2 flares when B cells were depleted and he was not able to reduce prednisone below 20 mg/day. A 6th patient had a flare when B cells recovered and retreatment with RTX re-induced and maintained remission. The median mRS score at last visit (median: 2; range 0-4) was lower than that prior to treatment (median 3; range 1-5). The median prednisone daily dose before RTX administration was significantly higher than that at last follow-up (p = .006). In the literature review, we identified 5 papers describing 7 patients treated with RTX. Six patients responded to RTX with clinical and MRI improvement with no reported flares after RTX treatment. CONCLUSIONS:Our data support a potential role for RTX treatment in selected patients with PCNSV.

journal_name

Autoimmun Rev

journal_title

Autoimmunity reviews

authors

Salvarani C,Brown RD Jr,Muratore F,Christianson TJH,Galli E,Pipitone N,Cassone G,Huston J III,Giannini C,Warrington K,Hunder GG

doi

10.1016/j.autrev.2018.12.002

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

399-405

issue

eissn

1568-9972

issn

1873-0183

pii

S1568-9972(19)30034-5

journal_volume

pub_type

杂志文章,评审

在线工具

Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature.